This post is for paying subscribers only
FDA Rejects Friedreich's Ataxia Drug Vatiquinone
The FDA declined PTC Therapeutics' vatiquinone for Friedreich's Ataxia, citing insufficient efficacy data and requiring more studies.
The FDA declined PTC Therapeutics' vatiquinone for Friedreich's Ataxia, citing insufficient efficacy data and requiring more studies.
FDA accepted cytisinicline NDA for smoking cessation, with a PDUFA date of June 20, 2026. This marks a significant step, potentially offering the first new FDA-approved therapy in two decades to combat nicotine dependence, supported by strong clinical data and safety.
Macy's reports its first same-store sales growth in 12 quarters, beats Q2 earnings expectations, and raises full-year guidance, signaling its turnaround strategy is gaining traction.
TVA, ENTRA1, & NuScale partner for 6 GW SMR nuclear expansion to power 4.5M homes or 60 data centers. This public-private initiative boosts energy security, meets soaring demand from AI/tech, and validates NuScale's SMR technology.